Background: The purpose of this study was to examine swallowing-related lower cranial nerve
| I N T R O D U C T I O N
The epidemiology of oropharyngeal cancer has changed dramatically in recent decades as the incidence of human papillomavirus (HPV)-associated disease has increased and tobacco-associated disease has decreased. 1, 2 In this same time, survival rates with oropharyngeal cancer steadily improved and organ-preservation regimens of radiation and chemoradiation replaced radical surgical methods as the primary modality for treating oropharyngeal cancer. Projections suggest that the number of oropharyngeal cancer survivors will continually rise over the next 2 decades, 2 and the majority of these survivors will have received curative doses of radiotherapy in excess of 65 Gy. Consequently, an ever-growing number of patients with HPV-associated oropharyngeal cancer have the potential for long-term cure surviving decades after their index cancer, mandating an unprecedented focus on late effects of therapy for oropharyngeal cancer.
Radiation-associated cranial neuropathy is a rare but functionally devastating late effect of head and neck radiotherapy. Cranial nerves are widely regarded as relatively radioresistant structures. However, over the decades, small cohort studies have examined lower cranial nerve palsy (LCNP) among head and neck cancer survivors, [3] [4] [5] [6] principally among patients with nasopharyngeal cancers (NPC), suggesting a long latency, the potential for progressing polyneuropathies, and implicating various central and peripheral mechanisms of denervation. The potential for radiation-associated LCNP in non-NPC head and neck cancer survivors has rarely been examined in published reports. Yet, with exceptional numbers of oropharyngeal cancer survivors achieving long-term disease control, recent case reports highlight the potential for de novo LCNP as a previously unexpected late effect of even modern conformal intensity-modulated radiotherapy (IMRT) for oropharyngeal cancer. 7, 8 In this report, we examine incidence, latency, and patterns of delayed LCNP after oropharyngeal IMRT with particular interest in implications on long-term swallowing function.
| MATERIALS A ND METHODS

| Study design and eligibility
A pooled dataset was analyzed from 2 institutional single-arm organpreservation trials for locoregionally advanced-stage head and neck cancer. Trial databases were sampled to include patients treated with definitive IMRT and systemic therapy for stages III-IV squamous cell carcinoma of the oropharynx with a minimum of 1-year disease-free survival after enrollment. Among 64 patients with oropharyngeal cancer enrolled, we excluded patients treated with the 3D conformal technique (n 5 2), <1-year disease-free follow-up (n 5 2), and we also excluded a single patient who discontinued radiotherapy against medical advice after 41 Gy in 19 fractions. Protocols were approved by the local institutional review board and all patients provided informed consent for trial participation.
| Treatment
All included patients received definitive IMRT with systemic therapy.
Fifty-five patients (93%) were treated with a split-field technique (IMRT delivered to the primary tumor and upper neck, whereas levels III and IV were treated with an anterior portal and lower larynx shielding).
Thirty-six patients were treated on an induction chemotherapy Paclitaxel Carboplatin Cetuximab trial, 9,10 and the remaining 23 patients
were on a trial of adaptive-IMRT. 11 Trial details and clinical reports have been published elsewhere, and are briefly reviewed below.
| Induction trial
After a loading dose of cetuximab 400 mg/m2 intravenously, patients received 6 weekly cycles of cetuximab 250 mg/m2 and paclitaxel 135 mg/m2 followed by carboplatin area under the curve 2 followed by 
| Statistical methods
Descriptive statistics were calculated and graphically plotted. The chisquare test or Fisher exact test were used to test differences of categorical variables and the Wilcoxon rank-sum test or Kruskal-Wallis test were used to assess between group differences for continuous variables. Survival outcomes were estimated by the Kaplan-Meier method with logrank tests to examine between group differences. Times were censored at the last event-free contact. Cumulative incidence rates of late LCNP events were calculated with death or new disease (locoregional recurrence, distant metastasis, or second primary malignancy) as a competing risk. Effects of T classification and tumor site on cumulative incidence of late events were evaluated in the univariate setting using Gray's test. SAS version 9.2 and S-Plus version 8.04 were used for analyses. was reviewed with standard elements extracted on a study-specific form. Results were summarized in descriptive format.
| Literature review methods
| R E S U L T S 3.1 | Patient characteristics
Fifty-nine patients with oropharyngeal cancer treated with definitive IMRT and systemic therapy were included in this study. The median age at trial enrollment was 53 years, 81% were men, and all patients had stage III/IV disease. TNM classification, tumor site, and therapeutic combinations are detailed in Table 1 . Median overall survival was not yet reached; 5-year and 10-year overall survival rates were 98.2% and 87.3%, respectively (see Figure 1 ).
| Cranial neuropathies
Three patients developed delayed hypoglossal palsy ipsilateral to the index oropharyngeal tumor with a median latency of 6.7 years (range 4.6-7.6 years; Table 2 ). At a median follow-up of 5.7 years, 5% of the enrolled patients had developed lower cranial neuropathy. Cumulative incidence of cranial neuropathy is illustrated in Figure 2 . LCNP cumulative incidence rates estimated from competing risk analysis were 6- Figure 4 . 16, 23 Hypoglossal nerve palsy was the most frequently reported radiation-associated LCNP. The median latency of onset measures for any LCNP ranged from 2.9-7.9 years.
4,23
The upper limit was reported at 34 years, 24 and the lower limit at 1 year. 25 Case reports and case series examining radiation-associated LCNP are summarized in Supporting Information Tables   S1  3,7 Table 3 33,34 and Supporting
Information Tables S1 and S2, respectively.
| DISCUSSION
Radiation-associated LCNP is commonly recognized as a rare late effect of radiotherapy for NPC but is infrequently reported in non-NPC survivors. With the ever-growing numbers of oropharyngeal cancer survivors, case reports are emerging that suggest that clinicians now increasingly encounter LCNP in long-term survivorship after curative radiotherapy or chemoradiotherapy for oropharyngeal cancer. 1, 7, 8 Results of this cohort analysis suggest that LCNP is indeed a potential late effect of oropharyngeal IMRT, detected in 3 of 59 survivors in this study. LCNP seems to be associated with both clinician-detected and patient-detected deterioration in swallowing function and associated decrements in quality of life in long-term survivorship.
The source of injury in radiation-associated LCNP is debated. In our review of the literature, authors speculated as to the various sources of injuries in patients who develop radiation-associated LCNP, but the with XII cranial nerve paralysis (CNP) after radiotherapy, and radiation was the cause of denervation in the majority of patients. 5 Others have suggested that upper CNP is more often a result of tumor invasion, whereas LCNP is typically a result of radiation injury. 23 The debate of peripheral or central pathology causing radiation-associated damage can be considered only once tumor recurrence is excluded as the source of LCNP, as was the case in all patients examined in this cohort analysis.
In published literature, radiation-associated LCNP was most often hypothesized to be a result of compressive fibrosis and/or direct ischemic nerve damage. 25 For instance, necropsy in a single LCNP case revealed notable peripheral fibrosis surrounding the affected nerve with myelin loss and atrophy, but comparably no microscopic or macroscopic fibrosis in a control patient without LCNP. 4 The authors concluded that the probable location of source injury was peripheral because of fibrotic tissue pressure, vascular interference, and morphology of neural vascular vessels. 4 Another NPC case series supporting this notion of compressive fibrosis on the nerve tracts based this on the observation of "marked neck fibrosis" in 63% (12/19) of LCNP cases evaluated. 6 Although some suggest that permanent depletion of Schwann cells or nerve ischemia may contribute to functional injury, 26 many suggest that soft tissue fibrosis may be a substantive and more prevalent factor leading to radiation-associated LCNP than other sources. It is also possible that radiation-associated LCNP could be caused by central injury to the brainstem nuclei as a result of the higher dose that the bulbar region receives in some conformal methods, such as IMRT that spreads low-dose bath, circumferentially leading to higher brainstem dose relative to older parallel-beam methods. In NPC, the most common organ at risk for nerve injury is typically considered the carotid sheath in the lower nasopharyngeal region. 5 A retrospective cohort analyzing the potential risk factors of developing radiation-associated LCNP suggested that the possible exposure of 70 Gy or above to the carotid space as a potential source location of injury because of the cranial nerves' passage along the vessel, and we have similarly found a candidate dose threshold of mean 62 Gy to the superior pharyngeal constrictor region discriminating oropharyngeal cancer survivors with LCNP from non-LCNP controls. 17, 27 Several other studies also attributed fibrosis of the neurovascular bundle in the parapharyngeal region as the source location for radiation-associated LCNP. 18, 22 Historically, in 1977, Berger and Bataini 3 suggested that the location of injury can be determined by the number of nerves affected, suggesting that an isolated XII nerve palsy is presumably related to submandibular damage, isolated X nerve is related to carotid sheath damage, and any combination of X, XI, and XII nerves reflects skull base pathology. 
